AXIM Biotechnologies, Inc. and Medical Marijuana, Inc. have announced a strategic alliance focused on researching and developing applications for AXIM's patent covering water-soluble cannabinoids. The collaboration centers on AXIM's U.S. Patent No. 11,542,226 B2, which addresses a fundamental limitation of traditional cannabinoids: their inability to dissolve in water, significantly impairing absorption by the body.
Under the agreement, AXIM has assigned Medical Marijuana, Inc. a fifty percent right, title, and economic interest in the patent and all associated intellectual property. This includes rights to existing and future patents, licensing proceeds, and claims for past infringement. Concurrently, the companies entered into a consulting agreement where AXIM will provide research and development services focused on developing applications for the patent technology.
Catalina Valencia, AXIM President, stated that the alliance presents both companies with the ability to accelerate uses of the patent technology. "The water solubility of CBD and other cannabinoids is a significant development for the improved administration and increased potency of cannabinoids," Valencia said. "We believe that the patent could result in the development of a drug or treatment, most likely in the form of sublingual administration, able to treat a variety of conditions including anxiety or seizures."
The patent technology offers several key advantages according to the companies. Through patented molecular engineering, the technology links cannabinoids to complementary compounds, substantially improving delivery mechanisms and therapeutic effectiveness. The engineered polyfunctional cannabinoids are more than 300 times more water-soluble than natural cannabinoids, enabling significantly improved absorption. These constructs are engineered to produce more potent responses than individual cannabinoid molecules, potentially allowing for lower therapeutic doses while avoiding toxic side effects associated with higher concentrations.
Dr. Scott, MJNA Chairman and President, expressed confidence in AXIM's ability to provide R&D support for developing commercialized uses of the patent technology. "The potential for developing enhanced administration of water soluble CBD and other cannabinoids for certain ailments and conditions is a major development for MJNA," Dr. Scott stated. "MJNA already has significant knowledge and exposure to the cannabinoid market and enjoys relationships in that arena."
Financial terms of the agreement include a $600,000 payment from MJNA to AXIM for the patent interest assignment, paid through a secured promissory note. The consulting agreement has an initial one-year term expiring in January 2027, with AXIM receiving $62,500 per month for research and development services. For more information about AXIM's broader diagnostic technology platform, visit https://www.aximbiotech.com.
The alliance represents a significant development in cannabinoid research, potentially expanding treatment applications for conditions where traditional oil-based cannabinoids have demonstrated limited bioavailability. The technology could enable development of sublingual applications and other delivery methods that improve therapeutic outcomes while reducing side effects. This collaboration combines AXIM's research capabilities with MJNA's market knowledge and relationships, potentially accelerating the commercialization of water-soluble cannabinoid technology across medical and therapeutic applications.
